Mindpath Health

Mindpath Health in Roseville, California offers Spravato (esketamine) for adults with treatment-resistant depression when psychiatry and therapy have not provided sufficient relief. As the only FDA-approved, self-administered nasal spray for treatment-resistant depression, Spravato is commonly used alongside antidepressant medications and therapy.

Patients self-administer Spravato twice weekly under clinician supervision and are observed in-office for two hours afterward, with the ongoing schedule determined after the first four weeks of treatment.

About half of esketamine patients report at least a 50% improvement in depressive symptoms, and roughly 30% achieve remission. The Roseville office also provides TMS, psychiatry, medication management, and therapy, and is in-network with most major commercial insurance plans in California.